Understanding Immuno-Oncology Assays and Their Role in Cancer Treatment

Understanding Immuno-Oncology Assays and Their Role in Cancer Treatment

Immuno-oncology assays play a vital role in cancer immunotherapy by helping detect biomarkers and monitor patient responses to treatment. These assays help identify biomarkers that can predict which patients are most likely to respond to certain immunotherapies. They also allow monitoring of patients' responses to immunotherapy by detecting changes in biomarker levels over the course of treatment.

Types of Immuno-Oncology Assays

There are several main types of immuno-oncology assays that are commonly used in clinical practice and cancer immunotherapy research.

Companion Diagnostic Assays

Companion diagnostic assays are used to identify biomarkers that help predict which patients will best respond to a specific immunotherapy drug or treatment approach. For example, PD-L1 immunohistochemistry assays are companion diagnostics for PD-1 and PD-L1 inhibitor drugs like pembrolizumab and atezolizumab. They detect PD-L1 protein expression on tumor cells to identify patients more likely to respond to these immunotherapies. Other examples include assays for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) biomarkers which predict response to checkpoint inhibitor therapy in certain cancers.

Monitoring Assays

Monitoring assays are utilized during and after immunotherapy treatment to detect changes in biomarkers and assess patient response over time. These include assays that quantify levels of soluble biomarkers in blood samples, such as cytokines and chemokines released in response to immunotherapy. Changes in these biomarker levels can indicate whether a patient is having an immune response to treatment. Imaging tests like PET scans are also monitoring assays that help track physical response of tumors during therapy. Another example is tumor biopsy analysis which can detect treatment-related changes in immune cell infiltration of tumors.

Comprehensive Immunoprofiling Assays

Comprehensive Immuno-oncology assays  take a more broad approach by simultaneously analyzing multiple biomarkers to develop a more complete picture of a tumor's immunologic profile and microenvironment. For example, gene expression profiling assays can measure expression of thousands of genes related to immune pathways and checkpoints. This provides data to determine a tumor's pre-existing immunity and likelihood to respond based on its overall genetic profile. Immune cell profiling uses techniques like multiplex immunofluorescence to detect numerous immune cell populations within the tumor microenvironment and stroma.

Assay Applications in Specific Cancer Types

Immuno-oncology assays play an important role across many cancer types in bringing about personalized immunotherapy approaches. Here are some key applications:

Lung Cancer

PD-L1 IHC assays are used as companion diagnostics for first-line immunotherapy in non-small cell lung cancer (NSCLC). Studies have shown patients with ≥50% PD-L1 expression have improved outcomes from PD-1/PD-L1 inhibitor monotherapy. MSI/dMMR assays also predict response to PD-1 inhibitors in a subset of NSCLC patients. Monitoring ctDNA for mutant allele frequencies helps track tumor changes during treatment.

Melanoma

Companion diagnostics for melanoma focus on baseline biomarkers like LDH levels, tumor mutation burden, and PD-L1 expression. Monitoring CTLA-4 and PD-1 response markers during ipilimumab and anti-PD-1 therapy respectively allows insight into immune activation. Gene expression profiling aids assessment of overall tumor immunogenicity.

Colorectal Cancer

MSI/dMMR biomarker status identifies CRC patients likely to have exceptional responses to PD-1 inhibitors due to pre-existing high tumor mutational burden. Quantifying cytokines like IFNγ in blood indicates immunotherapy is activating anti-tumor immunity. Immunophenotyping characterizes tumor-infiltrating immune cell subsets.

The Role of Immuno-Oncology Assays in Cancer Research

Beyond clinical applications, immuno-oncology assays play a vital role in translational and basic cancer research. Developing new assays helps reveal underlying mechanisms of immune response and resistance. Key research areas include:

Biomarker Discovery

Research aims to discover novel biomarkers through multi-omics approaches like tumor genome/transcriptome analysis and functional immune profiling. This enhances understanding of tumor-immunity relationships.

Immune Monitoring

Assays monitor dynamic changes in circulating cytokines/chemokines, immune cells, and effector molecules during treatment. They provide insights into immune activation pathways induced by different immunotherapies.

Combination Strategies

Immune monitoring assays study biomarker changes from combining immunotherapies or chemo-immunotherapies to understand synergistic effects and resistance mechanisms.

Personalized Medicine

Assay development helps stratify patients and identify new subsets most likely to benefit from certain immunotherapies or combinations, advancing personalized treatment approaches.

 immuno-oncology assays have become crucial tools in cancer research, clinical applications and biomarker-driven treatment development. A better understanding of their capabilities will continue to translate into more effective immunotherapies and improved outcomes for cancer patients. Ongoing assay development will further advance individualized cancer immunotherapy strategies and predictive and monitoring biomarkers in oncology.

Get More Insights On Immuno-Oncology Assays

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)